Fri, Sep 19, 2014, 4:48 AM EDT - U.S. Markets open in 4 hrs 42 mins

Recent

% | $
Quotes you view appear here for quick access.

Momenta Pharmaceuticals Inc. Message Board

  • erp3359 erp3359 Jun 29, 2014 4:13 PM Flag

    VERY FAVORABLE RISK/REWARD HERE BUY WITH BOTH FISTS

    At wells fargo, very bullish statements on pipeline and that manta has built up a huge inventory ready for immediate release upon copaxone approval as FDA was rejecting desperate attempts by teva to delay with stall tactics and tainted studies. ((((((BUYING WITH BOTH FISTS))))). Laughing at shorts who argue risk here at $11 when MNTA already took a 50% haircut on old issues they continue to bring up in a feeble attempt to cast doubt on the future of MNTA which has multiple catalysts going forward

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Based on a recent Zacks writeup (8/29/14) ("Momenta expects the generic version of Copaxone to be available in the first quarter of 2017") why would they tie up inventory assets for such a long period?

      Sentiment: Buy

    • and MNTA has a large cash horde to buy time actually expectation is for approval soon very soon

    • Not so fast.

      The judge rejected Momenta/Sandoz and Mylan/Natco’s claims that the COPAXONE® patents are invalid and unenforceable and found that the purported generic versions of COPAXONE® for which Momenta/Sandoz and Mylan/Natco seek Food and Drug Administration (FDA) approval infringe those patents. This ruling should prevent the FDA from approving, and the defendants from selling their purported generic versions of COPAXONE® in the U.S. until the Orange Book patents expire on May 24, 2014. As a result of this ruling, Teva also believes that the defendants will be enjoined from selling their products until the process patent expires on September 1, 2015. Furthermore, any purported generic version of COPAXONE® would need to obtain FDA approval prior to being made available to the public. At this point, it is unclear what the requirements would be for approval of a purported generic synthetic peptide.

 
MNTA
11.60+0.20(+1.75%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Oracle Corporation
NYSEThu, Sep 18, 2014 4:04 PM EDT
Concur Technologies, Inc.
NasdaqGSThu, Sep 18, 2014 4:00 PM EDT
Rite Aid Corporation
NYSEThu, Sep 18, 2014 4:02 PM EDT